Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight
Clinical trial NCT07046182 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07046182
- Sponsor
- Zhengzhou University
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-21
- Primary completion
- 2028-05-26
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.